sv8
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
under
THE SECURITIES ACT OF 1933
HAEMONETICS CORPORATION
(Exact name of issuer as specified in its charter)
|
|
|
Massachusetts
|
|
04-2882273 |
(State of Incorporation)
|
|
(IRS Employer Identification Number) |
400 Wood Road, Braintree, Massachusetts 02184 (781) 848-7100
(Address and telephone number of Principal Executive Offices)
Haemonetics Corporation
2005 Long-Term Incentive Compensation Plan
(Full Title of the Plan)
James OShaughnessy, General Counsel
Haemonetics Corporation
400 Wood Road
Braintree, Massachusetts 02184
(781) 848-7100
(Name, address and telephone number of agent for service)
Copy to:
Mary Ellen OMara
Nixon Peabody LLP
100 Summer Street
Boston, Massachusetts 02110
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of large accelerated filer, accelerated filer and smaller reporting
company in Rule 12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer þ | |
Accelerated filer
o | |
Non-accelerated filer o | |
Smaller reporting company o |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed Maximum |
|
|
Proposed Maximum |
|
|
|
|
|
Title of Securities |
|
|
Amount to Be |
|
|
Offering Price |
|
|
Aggregate |
|
|
Amount of |
|
|
to be Registered |
|
|
Registered(1) |
|
|
Per Share |
|
|
Offering Price |
|
|
Registration Fee |
|
|
Common Stock, $.01 par value
Shares Not Previously
Registered(2) |
|
|
1,475,566 |
|
|
$52.55 |
|
|
77,540,993.30 |
|
|
4,326.79 |
|
|
Total |
|
|
|
|
|
|
|
|
$77,540,993.30 |
|
|
$4,326.79 |
|
|
|
|
|
(1) |
|
Also registered hereunder are such additional number of shares of Common Stock,
presently indeterminable, as may be necessary to satisfy the anti-dilution provisions of the
Plan to which this Registration Statement relates. |
|
(2) |
|
The registration fee has been calculated with respect to 1,475,566 shares
registered on the basis of the average price of $52.55 on the New York Stock Exchange on May
19, 2009. |
TABLE OF CONTENTS
This Registration Statement is being filed solely for the purpose of registering 1,475,566
additional shares of common stock of Haemonetics Corporation issuable pursuant to the 2005 Long
Term Incentive Compensation Plan (the 2005 Plan). A total of 3,100,000 shares of common stock were previously
registered on Form S-8 (Registration No. 333-136839).
Pursuant to Instruction E to Form S-8, the
contents of the Registration Statement on Form S-8 (Registration No. 333-136839) are herein
incorporated by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The Company hereby incorporates by reference the documents listed in (a) through (c) below.
In addition, all documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14
and 15(d) of the Securities Exchange Act of 1934 (prior to the filing of a Post-Effective Amendment
which indicates that all securities offered have been sold or which deregisters all securities then
remaining unsold) shall be deemed to be incorporated by reference in this Registration Statement
and to be a part thereof from the date of filing of such documents. Any statement contained herein
or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to
be modified or superseded for purposes of this Registration Statement to the extent that a
statement contained herein or in any other subsequently filed document which also is incorporated
or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement.
Any statement so modified or superseded shall not be deemed, except as so modified or superseded,
to constitute part of this Registration Statement.
(a) The Companys latest annual report filed pursuant to Section 13(a) or 15(d)
of the Securities Exchange Act of 1934 or the latest Prospectus filed pursuant to Rule 424(b) under
the Securities Act of 1933, which contains either directly or by incorporation by reference audited
financial statements for the Companys latest fiscal year for which such statements have been
filed.
(b) All other reports filed pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934 since the end of the fiscal year covered by the annual report or the
Prospectus referred to in (a) above.
(c) The description of the Companys Common Stock which is contained in the
Registration Statement filed by the Company under the Securities Exchange Act of 1934, including
any amendment or report filed for the purpose of updating such description.
2
Item 4. Description of Securities
Inapplicable.
Item 5. Interests of Named Experts and Counsel
The validity of the authorization and issuance of the Common Stock offered hereby will be
passed upon for the Company by James OShaughnessy, General Counsel of Haemonetics Corporation.
Mr. OShaughnessy holds options to purchase Common Stock, Restricted Stock Units and owns shares of
Common Stock.
Item 6. Indemnification of Directors and Officers
Incorporated by reference to Registration Statement on Form S-8 (Registration No. 333-136839)
Item 7. Exemption from Registration Claimed
Inapplicable.
Item 8. Exhibits
|
|
|
Number |
|
Description |
|
|
|
4A
|
|
Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan. |
|
|
|
5
|
|
Opinion of James OShaughnessy, General Counsel of Haemonetics
Corporation, as to legality of shares being registered and consent. |
|
|
|
23
|
|
Consents of Expertsincluded in Registration Statement under
heading Consent of Independent Public Accountants. |
Item 9. Undertakings
The undersigned Registrant hereby undertakes the following:
(a) The undersigned Registrant hereby undertakes:
3
(1) To file, during any period in which offers or sales are being made, a post-effective
amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent post-effective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the information set forth in the registration
statement;
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in
the registration statement.
Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is contained in periodic
reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or
Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.
(2) That, for the purpose of determining any liability under the Securities Act
of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of
the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the registrants annual report pursuant
to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plans annual report pursuant to Section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered
4
therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(c) The undersigned registrant hereby undertakes, that, insofar as indemnification for
liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the
registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
5
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Braintree, Massachusetts on May 22, 2009.
|
|
|
|
|
|
|
HAEMONETICS CORPORATION
|
|
|
By: |
/s/ Brian Concannon
|
|
|
|
Brian Concannon |
|
|
|
President and Chief Executive Officer |
|
|
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below constitutes and
appoints Brian Concannon his/her true and lawful attorneys-in-fact and agents, each acting alone,
with full powers of substitution and resubstitution, for him/her or in his/her name, place and
stead, in any and all capacities to sign any and all amendments or post-effective amendments to
this Registration Statement (or any registration statement for the same offering that is to be
effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the
same, with all exhibits thereto, and other documents in connection therewith, with the Securities
and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full
power and authority to do any perform each and every act and thing requisite or necessary to be
done in and about the premises, as fully to all intents and purposes as he/she might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting
alone, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
6
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has
been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
|
|
Signature |
|
|
|
Title |
|
Date |
|
|
|
|
|
|
|
/s/ Brian Concannon
Brian Concannon
|
|
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Christopher Lindop
Christopher Lindop
|
|
|
|
Chief Financial Officer and Vice
President Business Development
(Principal Financial Officer)
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Susan M. Hanlon
Susan M. Hanlon
|
|
|
|
Vice President Finance
(Principal Accounting Officer)
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Brad Nutter
Brad Nutter
|
|
|
|
Executive Chairman of the Board
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Lawrence C. Best
Lawrence C. Best
|
|
|
|
Director
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Susan B. Foote
Susan B. Foote
|
|
|
|
Director
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Ronald G. Gelbman
Ronald G. Gelbman
|
|
|
|
Director
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Pedro P. Granadillo
Pedro P. Granadillo
|
|
|
|
Director
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Mark W. Kroll
Mark W. Kroll
|
|
|
|
Director
|
|
May 22, 2009 |
|
|
|
|
|
|
|
/s/ Ronald L. Merriman
Ronald L. Merriman
|
|
|
|
Director
|
|
May 22, 2009 |
7